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Abstract
Modeling dose-response relationships of drugs is essential to understanding their
effect on patient outcomes under realistic circumstances. While intention-to-treat anal-
yses of clinical trials provide the effect of assignment to a particular drug and dose,
they do not capture observed exposure after factoring in non-adherence and dropout.
We develop Bayesian methods to flexibly model dose-response relationships of binary
outcomes with continuous treatment, allowing for treatment effect heterogeneity and
a non-linear response surface. We use a hierarchical framework for meta-analysis with
the explicit goal of combining information from multiple trials while accounting for
heterogeneity. In an application, we examine the risk of excessive weight gain for
patients with schizophrenia treated with the second generation antipsychotics paliperi-
done, risperidone, or olanzapine in 14 clinical trials. Averaging over the sample popu-
lation, we found that olanzapine contributed to a 15.6% (95% CrI: 6.7, 27.1) excess risk
of weight gain at a 500mg cumulative dose. Paliperidone conferred a 3.2% (95% CrI:
1.5, 5.2) and risperidone a 14.9% (95% CrI: 0.0, 38.7) excess risk at 500mg olanzapine
equivalent cumulative doses. Blacks had an additional 6.8% (95% CrI: 1.0, 12.4) risk
of weight gain over non-blacks at 1000mg olanzapine equivalent cumulative doses of
paliperidone.
1 Introduction
Decision makers in health care want to know which treatments are most effective and safe.
When the treatment in question involves drugs, dosing becomes a key feature to understand.
For example, in a randomized controlled trial (RCT) of antipsychotic drugs patients may not
fully comply with their assigned treatment, systematically exhibiting poor adherence to a
drug that causes adverse outcomes and biasing a naive analysis. If between-trial comparisons
are involved, differential prescription patterns and trial length introduce further discrepancies
in dosing between drugs. If properly handled, variation in dose is not necessarily problematic:
knowledge of the effect of a drug at a given dose may be as valuable to decision makers as
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the effect of assignment measured in an intention-to-treat (ITT) analysis comparing mean
outcomes between assignment groups. Thus, modeling observed dose-response relationships
can provide rich, generalizable, and unbiased answers to key questions of interest.
It is as important to understand whether dose-response curves differ among key patient
subgroups, a phenomenon known as treatment effect heterogeneity (TEH), in order to enable
optimal treatment decisions for diverse patient populations. In schizophrenia research, base-
line characteristics like age, gender, and race are likely to moderate the effect of treatment
on safety and efficacy [22, 6].
In most cases, estimating dose-response relationships entails observational causal infer-
ence of one or multiple continuous treatments. Efron and Feldman (1991) discuss compliance-
response curves in the presence of a control group. Imai and van Dyk (2004) generalized
propensity scores to continuous treatment regimes, while Angrist and Imbens (1995) used
instrumental variables to model a continuous measure of treatment intensity [8, 14, 2]. Dose-
response methods like these that have explicitly adopted a causal inference framework have
generally taken a frequentist approach. For reasons discussed further below, Bayesian esti-
mation can be preferable in this setting. At the same time, flexible regression techniques such
as splines are preferable as they negate the need to assume linearity of treatment effects.
Because dose-response relationships are likely to exhibit “threshold” or “plateau” effects,
whereby there may be little effect until a certain dose is reached or effects flatten at high
exposures, flexible modeling of the curves is essential.
RCT data provide key variables on dosing, outcomes, and potential confounders, but
a single RCT is typically not powered for a dose-response analysis, especially in the pres-
ence of non-linearity or TEH. Meta-analysis provides a crucial tool to combine information
across trials and assess the variation in estimates from different evidence sources[20]. Be-
cause it pools information, meta-analysis enables more precise and complex estimates that
may be underpowered in a single trial. However, meta-analysis is complicated when model-
ing flexible dose-response relationships because estimands (typically a smooth function) are
simultaneously defined by multiple parameters. In the environmental statistics literature,
Dominici et al (2002) used a Bayesian hierarchical spline model to estimate the effect of a
single continuous exposure to pollution on mortality across US cities [7]. Gasparinni et al
(2012) built up a frequentist framework for multivariate meta-analysis of temperature and
mortality, when the quantity of interest is a spline function defined by multiple parameters
[9]. However, these articles did not address inference in the context of multiple treatments
and potential TEH, which are key features of drug comparisons.
To summarize, there are at least 5 major challenges to dose-response estimation with
trial data. First, actual cumulative exposure is not randomized and is therefore confounded
by baseline variables. Second, non-linear treatment effect curves are defined by multiple
parameters simultaneously, complicating inference and the interpretation of results. Third,
TEH is crucial to providing guidance for decision makers dealing with diverse populations;
because single trials are rarely powered to detect TEH, combining data from multiple trials
is imperative. Finally, pooling information from multiple data sources must be accomplished
with an approach that can account for between-trial variance.
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To address these challenges we combine ideas from causal inference, meta-analysis, and
Bayesian inference. We adopt a Bayesian framework using hierarchical models that can
naturally incorporate multiple levels of heterogeneity, while posterior parameters of interest
can be summarized flexibly and intuitively. This latter point is particularly important in
non-linear settings where key elements of the posterior (e.g. dose-response functions) are
inherently defined by multiple parameters. A further advantage of the Bayesian approach
is intuitive incorporation of substantive information and regularization through the use of
priors. To our knowledge, there has been little discussion of Bayesian approaches in the
multiple continuous treatment setting, a gap we aim to fill in this paper.
We adjust for confounding by including controls in an outcome model. We allow for
estimation of flexible treatment effect functions through the use of B-splines, where the
spline coefficients are distributed hierarchically to partially pool information across trials.
Curves can be estimated for multiple distinct treatment drugs. We further define TEH
for a binary moderator, allowing separate curves to be estimated for key subgroups. We
introduce and discuss some inferential approaches that can provide powerful and intuitive
interpretation of posterior results in this complex setting.
The development of our methods is motivated by an application in psychiatry. Specif-
ically, we seek to understand the effects of second generation antispsychotics (SGAs) on
excessive weight gain (> 7% from baseline) under a range of doses. To accomplish this goal
we used clinical trial data obtained from the Yale Open Data Access (YODA) Project and
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), a large trial of SGAs.
Actual cumulative exposure was calculated by summing prescribed daily doses over the du-
ration of treatment (accounting for dropout). Adherence data in the form of pill counts or
injections was also incorporated when available. Because the potency of SGAs varies, we
placed them on the same scale by converting their cumulative doses to doses equivalent to
100mg of olanzapine (OLZ doses), a scaling approach used for comparisons in pyschophar-
macology [18, 17, 16]. Data from placebo arms is incorporated to estimate the intercept
(treatment free response) and coefficients of potential confounders with more precision. Fur-
ther details of our selection and handling of these trials can be found in Spertus et al (2018)
[21].
Table 1 summarizes key features of the data. Clearly, the rate of excessive weight gain
varies considerably between treatments, but so does actual cumulative exposure. Thus,
modeling the dose-response relationship is crucial to understanding the effect of SGAs on
weight gain. There are a number of complicating factors, including that some drugs were
measured in few trials and multiple baseline variables are likely to confound effect estimates.
We are also interested in understanding possible moderating effects of race, which have
serious ramifications for clinical practice. Past studies have found conflicting evidence on
race driven TEH in terms of efficacy, safety, and prescription patterns [22, 19, 5, 15, 13]. By
combining evidence across trials and using flexible hierarchical splines to model the dose-
response relationship, we aim to shed further light on this important question.
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Table 1: Characteristics of data by treatment group. %ile = percentile; OLZ = olanzapine
equivalent dose; PANSS = positive and negative syndrome scale (higher scores imply more
severe illness); SD = standard deviation; BMI = body mass index.
Treatment Group
Placebo Paliperidone Olanzapine Risperidone
# Subjects (N) 1368 3482 533 540
# Trials (J) 12 13 4 2
Outcome and Exposure
% ≥ 7% Weight Gain 4.8 10.4 17.1 11.3
50th (99th) %ile 100mg OLZ 0.0 (0.0) 6.4 (28.3) 4.2 (9.0) 2.6 (23.7)
Baseline Covariates
Mean Age (SD) 39.7 (11.9) 39.4 (11.7) 38.6 (11.1) 40.8 (11.8)
Mean PANSS (SD) 89.0 (15.1) 89.3 (13.8) 87.5 (17.1) 79.8 (14.7)
Mean BMI (SD) 27.0 (6.4) 26.9 (6.3) 27.7 (7.1) 28.6 (6.2)
% Female 37.6 38.1 31.0 34.4
% Black 18.3 17.6 15.6 9.4
2 Causal Inference
Although treatment assignment is randomized, realized exposure is not, so that we adjust
for potential confounding. Our framework for causal inference is based on the Rubin causal
model, and borrows ideas from the continuous treatment potential outcomes model formu-
lated in Imai and van Dyk (2004)[14].
2.1 Causal Model and Assumptions
For subject i in a sample of n subjects, let T i denote a vector of continuous treatment taking
values in a set T , where in our case we have 3 positive valued treatments such that T = R3+.
Yi ∈ {0, 1} denotes observed binary outcome and X i is a vector of baseline covariates. We
define the set of potential outcomes Y = {Yi(t); t ∈ T , i = 1...n}, where t is an ordinary
vector representing a specific realization of the random variable T .
For a given subject we are interested in estimating the function Yi(t) over T . However
T is uncountable when we are dealing with continuous treatment, while we only observe
a single value of Yi(t). We therefore assume a degree of homogeneity of treatment effect
and smoothness over subjects to generate a meaningfully precise estimate of the potential
outcomes. In addition we make the usual assumptions necessary to conduct causal inference.
Stable unit treatment value assignment means that there is only one type of treatment
within levels of treatment and that subjects do not interfere with each other, such that a sub-
ject’s potential outcomes are independent of other subjects’ potential outcomes. Positivity
means that any subject can (theoretically) receive any level of treatment, i.e:
0 < P(T i = t|Xi) ∀ t, i. (1)
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With a continuous treatment, positivity is not possible without making smoothness assump-
tions.
The ignorability assumption is particularly important in observational causal inference.
Ignorability implies that conditional on observed covariates potential outcomes are indepen-
dent of treatment, i.e:
Yi(t) ⊥ T i|X i ∀ t, i (2)
In a comparison of assigned treatment groups in a randomized trial, randomization helps
to ensure ignorability by design. In observational causal inference, it is essential to include
all confounders in X i or estimates will be biased. In contrast to Imai and van Dyk (2004),
we do not adjust for confounding by modeling the propensity function P(T i = t|Xi). We
instead adjust for confounding directly in the outcome model [14].
3 A Hierarchical Non-Linear Model
3.1 Notation and Basic Model
Let j ∈ {0, ...J} index trials. To assess the causal effect of treatment at varying doses we
posit the hierarchical non-linear logistic regression:
Yij ∼ Bernoulli{logit−1[fj(T ij,X ij)]}. (3)
This makes for a potentially very high-dimensional problem so we simplify by restraining
confounder effects to be additive, linear, and the same across trials. Furthermore, treat-
ment effects are specified to be additive. These two considerations lead to a relatively low
dimensional regression:
fj(T ij,X ij) = αj +
K∑
k=1
fjk(Tijk) +
P∑
p=1
βpXijp.
These treatment functions can be flexibly estimated using a B-spline basis. Under this
formulation, the exposures for each drug k are expanded into recursively defined power bases
with local support [12]. The bases are defined by boundary points and fixed knots placed
within the range treatment. After expansion into a dimension-L B-spline basis with elements
ηkl(T k) we express each treatment function as a weighted sum of its basis:
fjk(Tijk) = φjk1Tijk +
L∑
l=2
φjklηkl(Tijk). (4)
All between trial differences in treatment are expressed through φjkl.
To complete the model we specify priors on the confounder coefficients βp and hierarchical
priors on the intercept and coefficients of fjk. For the confounder coefficients we simply
specify the weakly informative prior:
βp ∼ t5(0, 2.5).
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This implies that, when confounders are binary or scaled to standard normality, most
of the prior mass is placed in the interval [-5,5], a sizable range on the log-odds scale[11].
Let φj = [φj1...φjK ] = [φj11, ...φj1L, ...φjK1...φjKL], be the length K × L concatenation of
all spline coefficients for each treatment function in trial j. Let the overall mean across
trials of the intercept be the scalar µα, and the mean treatment coefficients be µφ =
[µ11, ...µ1L, ...µK1...µKL]. The hierarchical prior is specified as:
[
αj
φTj
]
iid∼ NKL+1
{[
µα
µTφ
]
,Σ
}
where Σ = D(σ)ΩD(σ) (5)
Here the (KL + 1) × (KL + 1) covariance matrix Σ is decomposed into the product of
a diagonal matrix, D(σ), defined by a (KL + 1) vector of standard deviations σ, and a
(KL+ 1)× (KL+ 1) correlation matrix Ω. The entries of σ = [σα, σ11, ...σ1L, ...σK1, ...σKL]
represent the between trial variability of each hierarchically specified parameter. Priors for
the hierarchical parameters are specified as:
µα ∼ N (0,∞) (6)
µφkl ∼ t5(0, 2.5) (7)
σkl ∼ C+(0, 0.1) (8)
Ω ∼ LKJ(3) (9)
The prior on the intercept µα is completely non-informative. The t5(0, 2.5) priors on µφkl
are made to be weakly informative given the scaling of the exposure (discussed below) [11].
The half-Cauchy prior on σkl is designed to be slightly regularizing in the sense that it pulls
σkl towards zero and thus the trial specific estimates towards their group means, µα or µφkl
[10]. With C+(0, 0.1) about 95% of the prior mass is below 1.3, which pools the estimates
when there is little information at the trial level but allows for substantial variation if the
data are informative. Ω is a priori distributed according to a Lewandowski, Kurowicka, Joe
(LKJ) distribution, determined by a single hyperparameter, which we set equal to 3 to put
slightly more prior weight on the identity matrix [23, 3]. Thus, the covariance matrix Σ is
slightly regularized through the priors on σ and Ω, which is necessary when there is sparsity
with respect to φj, for example if all drugs are not studied in all trials.
3.2 Treatment Effect Heterogeneity
Treatment effect heterogeneity is accommodated by estimating separate curves within patient
subgroups. For example, we could estimate separate dose-response curves for females, black
patients, or older patients. Specifically, let the moderators M ⊂ X denote a subset of the
covariates that we are interested in assessing for possible treatment effect heterogeneity. For
simplicity here we posit that M = M is a single binary moderator.
The additive treatment effects within levels of Mij are of primary interest. We introduce
a new parameter θ = [θ1...θK ] = [θ11, ...θ1L, ...θK1...θKL], which parameterizes additional
6
curves for each treatment for subjects with Mij = 1, fixed across trials. The models for
curves within moderator levels are:
fjk(Tijk,Mij = 0) = φjk1Tijk +
L∑
l=2
φjklηkl(Tijk) (10)
fjk(Tijk,Mij = 1) = φjk1Tijk + θk1Tijk +
L∑
l=2
[
φjklηkl(Tijk) + θklηkl(Tijk)
]
. (11)
As above, the prior on θkl is t5(0, 2.5). Note that θ does not vary by trial, which implies
that the moderating effect is constant across trials. Thus, all trial level heterogeneity is still
expressed through φj. Also, the basis coordinates ηkl(Tijk) are the same for both subgroups.
For conciseness, we denote the set of all parameters as Υ. Draws from the posterior are
indexed by q = {1, ..., Q} and Υq indicates a single draw from the joint distribution of all
parameters.
3.3 Knot Placement and Degrees of Freedom
This specification assumes fixed knots, which allows for relatively fast computation and
simple hierarchical structure. Following Gasparinni et al (2012) [9], we suggest constructing
candidate models of increasing complexity by placing knots symmetrically at fixed quantiles
of each treatment: a model with 0 knots is linear in all treatment groups; a 1 knot model is
composed of B-splines with a knot at the median; a 2 knot model has knots at .33 and .66,
and so on. Boundary knots are placed at dose 0 and the average (across trials) maximum
quantile respectively. The lower boundary knot is placed at 0 because it is the natural lower
bound for exposure and there will be a high-density of points exactly at zero when there is
a placebo arm. We define separate bases for each treatment but they do not vary by trial
(as indicated by the ‘k’ subscript on the basis terms ηkl in equation (4)).
The final model used for inference can be selected from this candidate set using informa-
tion criteria. We propose the leave-one-out information criterion (LOO-IC) for fully Bayesian
comparisons [24]. The LOO-IC can be calculated using Pareto-smoothed importance sam-
pling on a pointwise log-likelihood matrix, a procedure implemented in the loo R package
[25]. The fit of the model sequence is typically concave up in increasing complexity, so a
good stopping rule is to fit models with more complexity until the LOO-IC stops decreasing
and starts to increase.
3.4 MCMC Diagnostics
Posterior draws can be efficiently sampled using Hamiltonian Monte Carlo in Stan and
typically only a few thousand draws are needed [4]. We use the R wrapper package brms,
which is a nice interface and has efficient Stan code built in [3]. The quality of the draws
should be assessed by examining trace plots for a few quantities (especially the log-posterior)
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to spot any pathologies. Convergence can be summarized by the Gelman-Rubin R-hat
statistic and all parameters should have an R-hat below 1.1 at convergence [11]. Graphical
and numeric posterior predictive checks provide an additional way to check the model and
find places where it does not fit the data well [11].
3.5 Interpretation and Inference
When the treatment effect is non-linear, the estimand of interest is not a single parameter
but a function or multiple functions, each defined by multiple parameters. The best way to
assess differences in treatments across doses, treatment types, and potential moderators is to
plot the functions defined by the parameters. We can visualize treatment effect heterogeneity
by plotting separate functions for each subgroup. We can also evaluate the functions across
the joint distribution of parameters and plot lower and upper credible intervals to visualize
uncertainty.
In the logistic regression case, the shape of the function depends somewhat on baseline
confounders because terms are not additive after mapping back from the logit to probability
scale. Thus the plots give curves for subjects with all baseline confounders set equal to zero.
If confounders are appropriately centered and indicators are well chosen, the curves reflect
treatment effects for “typical” subjects.
Another key quantity of interest is the average treatment effect at fixed doses. We
consider the risk difference, ∆(k, a) which is defined as the expected outcome if all subjects
were treated with treatment k at dose a minus the expected outcome if all subjects were
treated at no dose. A distribution on the risk difference is obtained by computing it for each
draw from the posterior:
∆q(k, a) = EX{E(Y |T k = a,X,Υq)− E(Y |T k = 0,X,Υq)}.
The posterior mean and credible intervals for ∆(k, a) can be computed from the Q draws
obtained.
We summarize comparisons by integrating over a range of doses and averaging over draws.
For example, we calculate the probability that drug 1 has the smallest effect among all drugs
over a range of doses a ∈ (0, A):
P{∆(k = 1) = mink∆(k)} = 1
Q
Q∑
q=1
∫ A
0
I
{
∆q(k = 1, a) = mink∆q(k, a)
}
da, (12)
The integral can be computed numerically by making a discrete mesh over the range of
doses (0, A). This quantity may be useful as a scalar summary of the treatment effects that
can be used for decision making. It is straightforward to compute the probability that a
drug has the greatest effect merely by taking the maximum instead of the minimum in 12.
Treatment effect heterogeneity can also be assessed by taking local average treatment
effects across subgroups. Letting M be a binary moderator of interest, we let ∆q(M = 1)
represent the risk difference in strata defined by M = 1 and calculate the distributions within
subgroups as:
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∆q(M = 1, a) = EX{E(Y |T k = a,M = 1,X,Υq)− E(Y |T k = 0,M = 1,X,Υq)} (13)
∆q(M = 0, a) = EX{E(Y |T k = a,M = 0,X,Υq)− E(Y |T k = 0,M = 0,X,Υq)}. (14)
Comparisons within drugs but across subgroups are then facilitated by appropriate func-
tions of ∆q(M = 1) and ∆q(M = 0). A particularly useful function is the difference curve
which we define as: ∆q(M = 1, a) − ∆q(M = 0, a). We simplify computation of the dif-
ference curve by ignoring the covariates X which change the intercept. This has the effect
of setting all covariates to their default values (assuming centered covariates) and allows
computation of a single representative curve instead of separate ones for each subject. The
posterior mean and credible intervals are defined at each dose a, and the entire difference
curve can be plotted. TEH can be assessed by examining the plotted difference curve, where
any significant deviation from 0 indicates there may be TEH at that dose. If there is no
TEH, the curves are merely offsets of each other and the difference curve will be zero along
the plotted range because the intercepts are subtracted off.
4 Application to OPTICS Trials
4.1 Model
We implemented the model described in section 3. A linear model provided a baseline for
comparison, and more complex models were built using splines and compared. Spline bases
were generated for each treatment using the bs R function, with knots placed at appropriate
percentiles. These locations were the 50th percentile for a 1 knot basis, 33rd and 66th for
a 2 knot basis, 25th, 50th, and 75th for a 3 knot basis, and so on. We built a model for
TEH by including race as a binary moderator variable (black, non-black) as in equations
(10) and (11). We tested models of increasing complexity (linear, 1 knot, 2 knots...) using
the LOO-IC, and stopped adding knots when the out-of-sample fit worsened.
4.2 Diagnostics
Convergence of our MCMC algorithms was indicated by examining trace plots and the fact
that all R-hat statistics were below 1.1. Graphical posterior predictive checks indicated that
the model accurately captured the marginal outcome distributions overall, within trials, and
within treatment groups. The maximum and minimum outcome proportions across trials
were also well captured.
The LOO-IC (standard error) was 3431 (97) for a linear model, 3416 (97) for a spline
model with a single knot, and 3423 (97) for a spline model with 2 knots. Thus LOO-IC
indicated that a spline with a single knot provided the best fitting model.
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Olanzapine Paliperidone Risperidone
Overall
0 to 100mg OLZ Equivalents 1.9 (-0.8, 5.6) 0.4 (-0.4, 1.1) 5.8 (-0.5, 13.6)
0 to 500mg OLZ Equivalents 15.6 (6.7, 27.1) 3.2 (1.5, 5.2) 14.9 (0.0, 38.7)
Non-Blacks
0 to 100mg OLZ Equivalents 1.5 (-0.9, 4.9) 0.5 (-0.3, 1.2) 4.9 (-0.7, 12.1)
0 to 500mg OLZ Equivalents 15.2 (6.2, 26.0) 3.1 (1.4, 5.0) 14.6 (0.3, 37.7)
Blacks
0 to 100mg OLZ Equivalents 4.5 (-3.9, 18.6) -0.3 (-3.1, 1.8) 11.5 (-3.0, 34.7)
0 to 500mg OLZ Equivalents 17.1 (2.2, 37.3) 4.1 (-1.2, 9.6) 16.0 (-5.3, 53.7)
Table 2: Risk differences for percent probability of 7% weight gain under various drugs and
OLZ equivalent doses. OLZ = olanzapine.
4.3 Inference
Table 2 displays average treatment effects of moving from zero dose (no treatment) to doses
equivalent to either 100mg or 500mg of olanzapine for all three treatments studied, along with
95% credible intervals. It is immediately apparent that higher doses increase the probability
of excess weight gain for all three drugs. Olanzapine and risperidone have the largest average
effects, but there is considerable uncertainty in their effect sizes as well.
Treatment effects along a range of exposures from 0 to 800mg OLZ equivalents are dis-
played in figure 1. Paliperidone has a small positive effect on the risk of weight gain across
doses. At high doses, the effect of treatment becomes very uncertain for olanzapine and
risperidone, likely due to the small number of subjects at those doses. The effects do seem
to level off at high doses of treatment, although the high variance in these dose regions
complicates the interpretation of these results.
Figure 2 captures paliperidone TEH over the range of exposure by subtracting the curves
for non-blacks from the curves for blacks. If the treatment has a greater effect on blacks, the
curve will be positive. We see that the curve deviates significantly from 0 starting at around
700mg OLZ equivalent doses, providing evidence of TEH for blacks at high-doses. Thus,
compared with non-blacks, black participants are expected to have an increased weight gain
rate of about 5% on average at 700mg OLZ equivalents or more of paliperidone. For the
other two drugs, 95% credible intervals covered 0 at all doses, indicating no evidence of TEH.
Due to the high levels of uncertainty, this is not very informative about whether there is
TEH for risperidone or olanzapine.
We used equation 12 to compute the posterior probabilities that each drug was the ‘best’
in that it had the smallest effect on weight gain over a range of exposure from 0 to 500mg
OLZ equivalents. All drugs had a high-number of observed cumulative exposures in this
range. Probabilities were estimated for both non-black and black subjects but were very
similar over this range. Paliperidone had a probability of .85, risperidone had a probability
of .06, and olanzapine had a probability of .09 of being the best. Thus the evidence strongly
suggests that paliperidone is least likely to cause excessive weight gain at low cumulative
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doses.
5 Discussion
In this paper, we introduced a framework for hierarchical modeling of non-linear treatment
effects with potential TEH. Our work was motivated by the need to address non-compliance
in RCTs and to gain a better understanding of antipsychotic safety effects across varying
cumulative exposure levels. Additionally, we sought to fill a gap in the evidence regarding
the moderating effect of race on antipsychotic safety. Our choice of safety outcome (excessive
weight gain) was influenced by the association between excess weight and hypertension, type
2 diabetes, and other risk factors for coronary artery disease. This relationship is especially
significant in the context of a rapid growth in SGA utilization in the U.S., partly driven by
their frequent use for off-label indications [1].
To answer these questions, a meta-analytic framework was needed since trials were not
designed to precisely estimate continuous treatment effects or TEH. The model we built
incorporated flexible treatment effect modeling through B-splines where the basis coefficients
are hierarchically defined to partially pool information across trials. Separate curves can be
estimated to assess TEH in the presence of binary moderators. Although we only assessed a
single binary moderator, it is straightforward to expand the model to incorporate additional
moderators. To assess TEH in a non-linear continuous treatment setting we introduced the
concept of difference curves, which allow visualization of the magnitude and uncertainty of
effect differences between groups hypothesized to have moderating effects over a range of
exposure values. Bayesian computation allow for difference curves to be computed quickly
and simply using posterior draws. Although our approach was motivated by the need to
assess SGA effects, it can generalize readily to other drug trials and applications outside
psychiatry where one or more continuous treatments are of interest.
Posterior predictive checks indicated that our model captured outcome distributions well
across trials and treatments. Comparison using LOO-IC favored a spline model with a single
knot, accounting for race as a binary moderator.
All drugs led to increased probability of weight gain over their range of exposures, though
olanzapine and risperidone provided very imprecise estimates of effect curves. There was
some evidence of a leveling off of the effects at higher doses, a feature that we were able
to capture using a non-linear model. In addition, we found evidence that race moderates
the paliperidone’s association with weight gain, with increased risk of weight gain for black
subjects. Nevertheless, paliperidone was likely the best among the alternatives we considered
for both blacks and non-blacks. We were unable to find any realistic level of moderation of
race for risperidone or olanzapine due to high levels of uncertainty.
A major challenge in our application, and one that is likely to arise in other multivariate
continuous treatment designs, is how to standardize exposures. We chose to use olanzapine
equivalent doses, but other absolute scales like chlorpromazine equivalents or recommended
daily doses are also possible. Another possibility is to scale the treatments relatively, e.g.
divide the treatment variables so 100 is always the maximum dose, but this could introduce
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Figure 1: Draws of dose-response curves for blacks and non-blacks within each drug. Thin
grey curves represent a single draw from the posterior, thick black curves are the posterior
mean, dotted black lines bound the 95% credible region for the curves, black points above and
below curves mark observed exposures and outcomes. Exposure is on the x-axis and ranges
from 0 to 800mg olanzapine equivalent. Y-axis is probability of >7% weight gain. Wide
credible intervals for risperidone and olanzapine reflect the fact that they were measured in
very few trials and there is evidence inconsistency across trials.
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Figure 2: Draws of TEH for paliperidone showing difference between expected outcome for
blacks and non-blacks over a range of exposures to paliperidone (x-axis). Thin grey lines
are individual draws from the posterior, solid black line is posterior mean curve, and dashed
black lines bound 95% credible interval. Curves above 0 indicate treatment affects blacks
more than non-blacks at that dose, with difference in probability of outcome given on y-axis.
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problems if certain drugs were included in the original trials at relatively higher doses. In
[21], we found results to be relatively robust to the specific scaling used. Another challenge
was that relatively few trials assessed olanzapine and risperidone (4 and 2 respectively),
leading to strong uncertainty in these estimates. A potential solution is to fully pool the
data for these drugs and not model them hierarchical, but this may bias inference by ignoring
trial-level heterogeneity. As more individual participant level trial data is made available,
it will be possible to use our framework with additional information to make more precise
inferences on more drugs and better understand optimal treatments for diverse subjects.
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A Posterior Predictive Checks
To check the fit of our model to the data, we tested the proportion of subjects experiencing
the outcome within treatment groups and the maximum/minimum proportion of outcomes
across trials. Both checks indicated the model fit the data well.
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Figure 4: Posterior predictive distributions showing proportions of outcomes in each treat-
ment group. Histograms show posterior predictive draws, vertical lines are observed values.
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